Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Development, content validation and feasibility of a decision aid tool for the treatment of women with menopausal symptoms.
Maturitas
January 2025
Theramex, London, UK. Electronic address:
Introduction: Despite research supporting menopause hormonal therapy for menopausal women, its use continues to decline in most European countries and the United States. Experts highlighted the need for global assessment tools to assist clinicians in evaluating treatment for symptomatic menopausal women, which led to the development of the Menopause Treatment Tool, with separate versions for women and healthcare professionals. Both versions of the tool focus on menopausal symptoms, risk levels and suggested actions; the women's tool is administered prior to the consultation, while the clinician tool is administered by the clinician during the clinical consultation.
View Article and Find Full Text PDFUpdates on neonatal cell and novel therapeutics: Proceedings of the Second Neonatal Cell Therapies Symposium (2024).
Pediatr Res
January 2025
Department of Paediatrics, Monash University, Melbourne, VIC, Australia.
Cell therapies as treatments for neonatal conditions have attracted significant research and parent interest over the last two decades. Mesenchymal stromal cells, umbilical cord blood cells and neural stem cells translate from lab, to preclinical and into clinical trials, with contributions being made from all over the world. Effective and timely translation involves frequent reflection and consultation from research-adjacent fields (i.
View Article and Find Full Text PDFOocyte donors' physical outcomes and psychosocial experiences: a mixed-methods study.
Fertil Steril
January 2025
Department of Health Behavior and Biological Sciences, School of Nursing, University of Michigan, Ann Arbor, Michigan.
Objective: To expand knowledge on physical outcomes and psychosocial experiences of oocyte donors after donation across 3 age cohorts.
Design: Cross-sectional mixed-methods survey.
Patients: A total of 363 participants (ages: 22-71 years, M = 38.
Somatic PTEN and ARID1A loss and endometriosis disease burden: a longitudinal study.
Hum Reprod
December 2024
Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada.
Study Question: Is there an association between the somatic loss of PTEN (phosphatase and tensin homolog) and ARID1A (AT-rich interaction domain 1A) and endometriosis disease severity and worse clinical outcomes?
Summary Answer: Somatic PTEN loss in endometriosis epithelium was associated with greater disease burden and subsequent surgical complexity.
What Is Known Already: Somatic cancer-driver mutations including those involving the PTEN and ARID1A genes exist in endometriosis without cancer; however, their clinical impact remains unclear.
Study Design, Size, Duration: This prospective longitudinal study involved endometriosis tissue and clinical data from 126 participants who underwent surgery at a tertiary center for endometriosis (2013-2017), with a follow-up period of 5-9 years.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!